NEUREN PHARMACEUTICALS LIMITED

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run.

Latest Threads

Tag

Subject

NEU

NEU chart

37 38 39

13/06/25

2.3K

1.3M

13/06/25

Last post GmundStables

2.3K

1.3M

NEU

Share Price

258 259 260

13/06/25

15K

7.5M

13/06/25

Last post What A Gas

15K

7.5M

NEU

Ann: Update - Notification of buy-back - NEU

13/06/25

420

13/06/25

Last post

ASX News

420

NEU

M&A

2 3 4

12/06/25

204

107K

12/06/25

Last post w_i_z_z_a

204

107K

NEU

Neuren Media and Analyst Coverage

28 29 30

12/06/25

1.7K

1.0M

12/06/25

Last post kens

1.7K

1.0M

NEU

Ann: Update - Notification of buy-back - NEU

12/06/25

2.1K

12/06/25

Last post baldwidx

2.1K

NEU

Angelman trial

11/06/25

101

60K

11/06/25

Last post Piton72

101

60K

NEU

Ann: Update - Notification of buy-back - NEU

11/06/25

568

11/06/25

Last post

ASX News

568

See All Discussions

Timeline

Update - Notification of buy-back - NEU
13 Jun 08:26	Share

Update - Notification of buy-back - NEU
12 Jun 07:45	Share

Update - Notification of buy-back - NEU
11 Jun 08:07	Share

Update - Notification of buy-back - NEU
10 Jun 08:33	Share

Update - Notification of buy-back - NEU
06 Jun 09:13	Share

Update - Notification of buy-back - NEU
05 Jun 07:50	Share

Notification of cessation of securities - NEU
04 Jun 16:30	Share

Update - Notification of buy-back - NEU
04 Jun 08:30	Share

Update - Notification of buy-back - NEU
03 Jun 08:38	Share

Update - Notification of buy-back - NEU
02 Jun 08:51	Share

Update - Notification of buy-back - NEU
30 May 08:41	Share

Update - Notification of buy-back - NEU
29 May 08:00	Share

Update - Notification of buy-back - NEU
28 May 07:31	Share

Results of Meeting
27 May 12:17	Share

AGM Chair Address & CEO Presentation
27 May 10:19	Share

Update - Notification of buy-back - NEU
27 May 08:41	Share

Update - Notification of buy-back - NEU
26 May 09:11	Share

Notification regarding unquoted securities - NEU
23 May 17:15	Share

Approval of long-term equity incentive
23 May 11:51	Share

Update - Notification of buy-back - NEU
23 May 08:43	Share

Update - Notification of buy-back - NEU
22 May 08:21	Share

Update - Notification of buy-back - NEU
21 May 07:31	Share

Update - Notification of buy-back - NEU
20 May 08:26	Share

Update - Notification of buy-back - NEU
19 May 08:52	Share

Update - Notification of buy-back - NEU
16 May 09:11	Share

Update - Notification of buy-back - NEU
15 May 08:00	Share

Update - Notification of buy-back - NEU
14 May 08:20	Share

NEU receives FDA minutes and re-confirms Phase 3 endpoints
13 May 14:06	Share

Update - Notification of buy-back - NEU
13 May 09:04	Share

Update - Notification of buy-back - NEU
12 May 09:09	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	266	13.100
1	667	13.080
1	1400	13.070
5	5127	13.060
3	3154	13.000

Price($)	Vol.	No.
13.150	1619	2
13.190	1305	1
13.220	3345	3
13.240	3608	3
13.250	3081	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Neuren set for FDA talks on trial to treat developmental genetic disorders

Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial.

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News